Steering innovation in cancer therapeutics

AUM’s value driven drug development process for innovative cancer therapeutics, is a culmination of several decades of research in the treatment of Asia-prevalent cancers. With a singular goal of making cancer treatment accessible and affordable to all, AUM is led by a team of clinicians and medical researchers with global & diverse, clinical and commercial experience of 100+ years. Every stakeholder is passionate about what they do, with an emphasis on democratising cancer management and treatment.

vishal-doshi
VISHAL DOSHI, Chairman, Chief Executive Officer
  • Extensive experience in structuring and managing risk sharing deals in various roles worth over $1 billion USD.
  • Extensive experience in clinical research across the pharmaceutical and CRO industry, spanning US, Europe and Asia
  • Key Opinion Leader to Korean Health Industry Development Institute
  • Previously held senior business development and management roles at IQVIA, EPS International and ICON
  • Master’s Degree in Pharmaceutical Sciences from Kingston University with research focus in Aromatase inhibitors in Breast cancer
  • Bachelor of Pharmacy from University of Mumbai
zou-bin
Dr. HARISH DAVE, Co-Founder, Chief Medical Officer
  • Board-certified oncologist and hematologist with more than 35 years of experience
  • Conducted over 100 studies in hematology, oncology and transplantation
  • Extensive experience in managing regulatory authorities including successful submission of over 50 INDs
  • Structured and executed a private equity Novaquest–sponsored strategic virtual drug development collaboration between Quintiles and Eisai
  • Held various senior management positions at IQVIA, George Washington University Medical Center and VA Medical Center in Washington
harish-dave
TERIG HUGHES, Chief Financial Officer
  • Over 25 years of international experience in healthcare, scientific and medical publishing, information and analytics
  • Extensive financial management experience in growing businesses, with portfolios up to $400 million in annual turnover
  • M&A experience spanning Europe, USA and Asia and deals ranging from a $2 million JV formation with a leading Chinese University to integration of a $4.5 billion acquisition in the US
  • Previous senior leadership roles in Asia with Elsevier, as Finance Director for the Health Sciences Division, and Managing Director for India and South East Asia
john-patava
Dr. JOHN PATAVA, Chief Operating Officer
  • 25 years of experience in medical research and clinical development of therapeutics products, including a 10-year period leading clinical operations at Bayer
  • Global Head of Scientific Affairs at Sirtex Technology Pty Ltd, an Australian listed oncology company, where he managed a global clinical operations budget in excess of A$20 million
  • Successfully delivered Sirtex’s global pivotal studies with a combined enrolment of 1103 patients, in over 200 investigator sites in 24 countries
  • Global Head of Biosimilar Development Business Group within Quintiles
  • Managed clinical trials in the indications of oncology, renal medicine, Chron’s disease, multiple sclerosis, hematology and surgery.
terig-hughes
Dr. ZOU BIN, Chief Scientific Officer
  • Has developed multiple preclinical candidates among which NITD609 entered phase II clinical trials.
  • Co-inventor of a number of patents and has been featured in more than twenty publications in high impact journals, including Science and Nature
  • Previously worked at Shanghai Blueray Biopharma, Co., Ltd. as CEO and Co-founder, and was responsible for developing a strong pipeline of lymphoma/lung cancer drugs, taking the company’s value to more than 100 million RMB.
  • PhD and post-doctoral fellowship in synthetic chemistry with Prof. Dawei Ma (Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences) and Prof. K. C. Nicolaou (Institute of Chemical and Engineering Sciences, A*STAR, Singapore).